PER2 and ovarian carcinoma: Wang et al. (Wang et al., 2020d) found a link between the downregulation of PER2 gene expression in cisplatin-resistant ovarian cancer cells and the PI3K/AKT signaling pathway, which led to the activation of the multidrug resistance gene 1 (MDR1).